Jan 9, 2008 | NEWS
Reykjavik, ICELAND, January 9, 2008 – deCODE genetics (Nasdaq:DCGN) today announced positive topline results from its Phase IIa clinical trial for DG051, the company’s leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these...
Jan 6, 2008 | NEWS
Reykjavik, January 6, 2008 – deCODE scientists today report that the genetic variant on chromosome 9p21 that the company has linked to increased risk of heart attack is also associated with up to 70% increase in risk of abdominal aortic aneurysm (AAA) and intracranial...
Dec 19, 2007 | NEWS
Give the holiday gift that can unlock the genome Reykjavik, ICELAND, Dec. 19, 2007 – deCODE genetics (Nasdaq:DCGN) today announced the availability of deCODEme™ gift certificates that allow individuals to give the gift that enables friends and family to get a detailed...
Nov 16, 2007 | NEWS
The company that has led in the discovery of genes that confer risk of common diseases is empowering individuals to explore their own genome Reykjavik, ICELAND, Nov. 16, 2007 – deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODEme™, a pioneering service...
Nov 2, 2007 | NEWS
Tests Detect Major Common Genetic Risk Factors for Heart Attack and Stroke Orlando, Florida, November 4-7, 2007 – At this year’s Scientific Sessions of the American Heart Association, deCODE genetics (Nasdaq:DCGN) is presenting its newly launched DNA-based...
